Buoyed by booming sales of its diabetes drugs, Eli Lilly (NYSE:LLY) was the best performing large pharma or biotech in H1 2023, returning an impressive 28%.
Coming in second, Vertex Pharmaceuticals (VRTX), helped by continued strong revenue from its cystic fibrosis portfolio, returned ~23%.
Support authors and subscribe to content
This is premium stuff. Subscribe to read the entire article.
Login if you have purchased